Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
03/2009
03/19/2009WO2009033789A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033788A2 Use of a jck-301, optionally in combination with big endothelin, as a therapeutic agent.
03/19/2009WO2009033787A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033786A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033785A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
03/19/2009WO2009033784A2 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
03/19/2009WO2009033783A2 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis
03/19/2009WO2009033782A2 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
03/19/2009WO2009033781A2 Use of k237 as therapeutic agent
03/19/2009WO2009033780A2 Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
03/19/2009WO2009033778A2 Mage-3 antigen and others for use as a therapeutic agent
03/19/2009WO2009033777A1 Leuprolide analog as a therapeutic agent
03/19/2009WO2009033776A1 Use of a defensin peptide as a therapeutic agent
03/19/2009WO2009033775A2 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent
03/19/2009WO2009033772A1 Use of a peptide as a therapeutic agent
03/19/2009WO2009033771A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033770A2 Calcitonin c-terminal flanking peptide for use as a therapeutic agent
03/19/2009WO2009033769A2 Use of cortistatin 14 and others as a therapeutic agent
03/19/2009WO2009033768A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033767A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033766A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033765A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033763A1 Nafarelin and carboxymethyl-phe-leu as therapeutic agents
03/19/2009WO2009033762A2 Use of endothelin-3 as a therapeutic agent
03/19/2009WO2009033761A2 Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent
03/19/2009WO2009033760A2 Use of fibronectin fragment (196-203 ) as a therapeutic agent
03/19/2009WO2009033759A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033758A2 Use of the peptide phpfhffvyk as therapeutic agent
03/19/2009WO2009033757A2 Use of mage-3 antigen (271-279) as a therapeutic agent
03/19/2009WO2009033756A2 Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent
03/19/2009WO2009033755A2 Use of l-carnosine as a therapeutic agent
03/19/2009WO2009033754A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033751A2 Use of leu-enkephalin as a therapeutic agent
03/19/2009WO2009033750A2 Use of phm-27 alone or in combination with leu-enkephalin as a therapeutic agent
03/19/2009WO2009033749A2 Use of thymopentin as a therapeutic agent
03/19/2009WO2009033748A2 Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
03/19/2009WO2009033747A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033746A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033745A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033744A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033741A2 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
03/19/2009WO2009033740A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033739A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033738A2 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
03/19/2009WO2009033736A2 Use of met-enkephalin as a therapeutic agent
03/19/2009WO2009033735A2 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
03/19/2009WO2009033734A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033733A2 Use of apeptide as a therapeutic agent
03/19/2009WO2009033732A2 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
03/19/2009WO2009033731A2 Use of a laminin peptide as a therapeutic agent
03/19/2009WO2009033730A2 Peptide gxgrgdspca as a therapeutic agent
03/19/2009WO2009033729A2 Therapeutic uses of gastrin- 1 and g- pen-grgdspca
03/19/2009WO2009033726A2 Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent
03/19/2009WO2009033725A1 Use of human neuropeptide as a therapeutic agent
03/19/2009WO2009033724A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009WO2009033723A2 Use of aip2 as a therapeutic agent
03/19/2009WO2009033722A2 Use of a octreotide as a therapeutic agent
03/19/2009WO2009033721A2 Use of salusin beta alone or in combination with octreotide as a therapeutic agent
03/19/2009WO2009033720A1 Mastoparan for the treatment of diseases
03/19/2009WO2009033719A2 Use of a deslorelin and mastoparan as a therapeutic agent
03/19/2009WO2009033718A2 Use of anti -inflammatory peptide 1 as a therapeutic agent
03/19/2009WO2009033717A2 Use of gonadorelin as a therapeutic agent
03/19/2009WO2009033714A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033712A2 Use of melanotan ii as a therapeutic agent
03/19/2009WO2009033711A2 Use of glp-1 as a therapeutic agent
03/19/2009WO2009033710A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine
03/19/2009WO2009033707A2 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
03/19/2009WO2009033701A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033700A1 Use of secretin and optionally urodilatin as therapeutic agents
03/19/2009WO2009033696A1 Use of a peptide pyx-1 as a therapeutic agent
03/19/2009WO2009033692A2 Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents
03/19/2009WO2009033690A1 Bfgf (119-126) for therapeutic applications
03/19/2009WO2009033687A1 Spantide ii and bfgf (119-126) for therapeutic applications
03/19/2009WO2009033684A1 Minigastrin as a therapeutic agent
03/19/2009WO2009033681A2 Cyclo-argd as a therapeutic agent
03/19/2009WO2009033680A2 Galanin-like peptide alone or in combination with cyclo-argd as a therapeutic agent
03/19/2009WO2009033678A2 Use of a tuftsin as a therapeutic agent
03/19/2009WO2009033669A2 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
03/19/2009WO2009033668A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033667A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033666A2 Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
03/19/2009WO2009033665A2 Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
03/19/2009WO2009033664A1 Use of delta-endorphin as a therapeutic agent
03/19/2009WO2009033663A1 Use of fertirelin and delta-endorphin as therapeutic agents
03/19/2009WO2009033661A2 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
03/19/2009WO2009033660A2 Use of octreotide as a therapeutic agent
03/19/2009WO2009033659A1 Hcv protease inhibitor and octreotide as therapeutic agents
03/19/2009WO2009033658A1 (d-leu7 ) -histrelin as a therapeutic agent
03/19/2009WO2009033657A2 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
03/19/2009WO2009033656A2 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
03/19/2009WO2009015812A3 Prodrugs of 2-amino-6- ( { [2- (4-chlorphenyl) -1, 3-thiaz0l-4-yl] methyl}thio) -4- [4- ( 2 -hydroxyethoxy) phenyl] pyridin-3, 5-dicarbonitrile
03/19/2009WO2009001144A3 Pharmaceutical aerosol compositions comprising fluticasone
03/19/2009WO2008039139A8 Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
03/19/2009WO2008039138A8 Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
03/19/2009WO2007122580A3 Compositions of phenylephrine useful for treatment of respiratory illness
03/19/2009US20090076256 Degradation-resistant mononucleoside phosphate compounds
03/19/2009US20090076152 Novel Compounds Active as Muscarinic Receptor Antagonists
03/19/2009US20090076120 Crystal of Aminopyrrolidine Derivative and Production Method Thereof
03/19/2009US20090076101 Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors
03/19/2009US20090076061 Muscarinic acetycholine receptor antagonists
1 ... 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 ... 878